Metal oxide encapsulated drug compositions and methods of preparing the same

Abstract

To provide a pharmaceutical composition having a drug-containing core enclosed by one or more metal oxide materials, and to provide a method of preparing the same.SOLUTION: Provided is a composition comprising coated particles including an antibody-containing core enclosed by a coating layer, the antibody-containing core comprising a freeze-dried or spray-dried antibody, the coating layer being conformal and comprising an inorganic oxide selected from the group consisting of aluminum oxide, titanium oxide, and zinc oxide, the coating layer having a thickness ranging from 0.1 nm to 100 nm.SELECTED DRAWING: Figure 1

Description

[Technical Field]

[0001] This disclosure relates to pharmaceutical compositions and methods for preparing metal oxide encapsulated drugs at process temperatures of 35° C. or less. [Background technology]

[0002] It is important to the pharmaceutical industry to develop drug-containing pharmaceutical compositions (e.g., small molecules, virus particles, polypeptides, polynucleotides, mixtures of polypeptides and lipids, or mixtures of polynucleotides and lipids, small molecules, virus particles, polypeptides, polynucleotides, mixtures of polypeptides and lipids, or mixtures of polynucleotides and lipids) that have improved flowability, extended shelf life, improved solubility, and contain a high fraction of drug that is functional before or after administration of the pharmaceutical composition to a subject in need. These properties may reduce the associated manufacturing cost per therapeutic dose. These properties may also increase the commercial value or likelihood of government approval of the pharmaceutical composition by (i) enabling or increasing the safety, predictability, and success rate of the preparation method; (ii) improving the stability of the drug over time, e.g., during preparation of the pharmaceutical composition and / or under storage conditions prior to administration; (iii) increasing the solubility of the drug; and / or (iv) reducing the amount of the pharmaceutical composition that must be administered to a subject in need of one or more therapeutic benefits. Numerous coating techniques have been developed for encapsulating drugs, such as polymer mesh coating, pan coating, aerosol coating, fluidized bed reactor coating, molecular layer deposition coating, and atomic layer deposition coating. Despite advances in compositions and methods for preparing encapsulated drugs, pharmaceutical compositions prepared by known methods often exhibit poor flowability and / or contain drugs that, for example, degrade during the preparation process. Thus, there remains an unmet need for new compositions and methods for preparing encapsulated drugs. The present invention addresses this need, particularly for metal oxide-encapsulated drugs. Summary of the Invention

[0003] In one aspect, a method for preparing a pharmaceutical composition having a drug-containing core surrounded by one or more metal oxide materials is provided. The method includes the following steps: (a) loading drug-containing particles into a reactor; (b) applying a vapor or gaseous metal precursor to the particles in the reactor; (c) performing one or more pump-purge cycles of the reactor using an inert gas; (d) applying a vapor or gaseous oxidizing agent to the particles in the reactor; and (e) performing one or more pump-purge cycles of the reactor using an inert gas. The temperature of the particles does not exceed 35°C. This produces a pharmaceutical composition having a drug-containing core surrounded by one or more metal oxide materials.

[0004] Implementations may include one or more of the following features.

[0005] The temperature inside the reactor does not need to exceed 35°C.

[0006] The sequence of steps (b)-(e) can be repeated one or more times to increase the overall thickness of the one or more metal oxide materials surrounding the core.

[0007] The reactor pressure can be stabilized during the next step (a), step (b), and / or step (d).

[0008] The contents of the reactor may be agitated before and / or during step (b), step (c), and / or step (e).

[0009] A subset of the vapor or gaseous contents may be pumped out prior to step (c) and / or step (e).

[0010] The metal oxide layer may have a thickness in the range of 0.1 nm to 100 nm.

[0011] The particles may include a drug and one or more pharmaceutically acceptable excipients.

[0012] The particles may have a median particle size, on a volume average basis, between 0.1 μm and 1000 μm.

[0013] The pharmaceutical composition may be removed from the reactor and mixed with a pharmaceutically acceptable diluent or carrier.

[0014] The particles may consist essentially of the drug.

[0015] The drug can be a small molecule, a viral particle, a polypeptide, a polynucleotide, a composition comprising a polypeptide and a lipid, or a composition comprising a polynucleotide and a lipid.

[0016] The one or more metal oxide materials may include aluminum oxide, titanium oxide, iron oxide, gallium oxide, magnesium oxide, zinc oxide, niobium oxide, hafnium oxide, tantalum oxide, lanthanum oxide, and / or zirconium dioxide.

[0017] The one or more metal oxide materials may consist of aluminum oxide and / or titanium oxide.

[0018] The oxidizing agent may be selected from the group of water, ozone, and organic peroxides.

[0019] The polypeptide may be an antibody or antibody fragment.

[0020] The antibody or antibody fragment may be selected from the group of alemtuzumab, bevacizumab, cetuximab, gemtuzumab ozogamicin, ipilimumab, ofatumumab, panitumumab, pembrolizumab, ranibizumab, rituximab, or trastuzumab.

[0021] The small molecule drug may be selected from the group of acetaminophen, clarithromycin, azithromycin, ibuprofen, fluticasone propionate, salmeterol, pazopanib HCl, palbociclib, or amoxicillin clavulanate potassium.

[0022] In another embodiment, pharmaceutical compositions having a drug-containing core surrounded by one or more metal oxide materials can be prepared by any of the methods described above.

[0023] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Methods and materials for use in the present invention are described herein; other suitable methods and materials known in the art can also be used. The materials, methods, and examples are illustrative only and are not intended to be limiting. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are hereby incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control.

[0024] Other features and advantages of the invention will become apparent from the following detailed description and drawings, and from the claims. [Brief explanation of the drawings]

[0025] [Figure 1] Schematic of a rotating reactor for ALD and / or CVD coating of particles, e.g., drugs. [Figure 2] Table showing typical process conditions for the method [Figure 3] Graph showing representative residual gas analysis traces taken during steps (d), (h), (i), and (m) for one cycle of the method. [Figure 4] (Top): Graph showing overlaid HPLC chromatograms of clarithromycin from compositions containing uncoated clarithromycin, aluminum oxide-coated clarithromycin, or titanium oxide-coated clarithromycin; (Bottom): Table showing values ​​quantified from the HPLC chromatograms. [Figure 5](Top): Graph of overlaid HPLC chromatograms of clarithromycin-carbomer complex (CCC) from compositions containing uncoated CCC, aluminum oxide-coated CCC, or titanium oxide-coated CCC; (Bottom): Table showing values ​​quantified from the HPLC chromatograms. [Figure 6] (Top): Graph of HPLC chromatograms overlaid with pazopanib from compositions containing uncoated pazopanib, aluminum oxide-coated pazopanib, or titanium oxide-coated pazopanib that were analyzed; (Bottom): Table showing values ​​quantified from the HPLC chromatograms. [Figure 7] (Top): Graph of HPLC chromatogram overlaid with palbociclib from compositions containing uncoated clarithromycin palbociclib, aluminum oxide-coated palbociclib, or titanium oxide-coated palbociclib; (Bottom): Table showing values ​​quantified from the HPLC chromatograms. [Figure 8] Graph showing the spectral patterns analyzed by MALDI-TOF of pazopanib HCl from compositions of uncoated pazopanib HCl, aluminum oxide coated pazopanib HCl, or titanium oxide coated pazopanib HCl. [Figure 9] Graph showing fragmentation patterns of pazopanib HCl from compositions of uncoated pazopanib HCl, aluminum oxide coated pazopanib HCl, or titanium oxide coated pazopanib HCl analyzed by MALDI MS / MS. [Figure 10] Graph showing the spectral patterns of palbociclib analyzed by MALDI-TOF from compositions of uncoated palbociclib, aluminum oxide-coated palbociclib, or titanium oxide-coated palbociclib. [Figure 11]Graph showing fragmentation patterns of palbociclib from compositions of uncoated palbociclib, aluminum oxide-coated palbociclib, or titanium oxide-coated palbociclib analyzed by MALDI MS / MS. [Figure 12] Graph showing the relative release of clarithromycin over time from uncoated clarithromycin, aluminum oxide coated clarithromycin, or titanium oxide coated clarithromycin as analyzed by UV spectroscopy. [Figure 13] Graph showing the relative release of clarithromycin-carbomer complex (CCC) over time from uncoated CCC, aluminum oxide-coated CCC, or titanium oxide-coated CCC, as analyzed by UV spectroscopy. [Figure 14] Graph showing the relative release of palbociclib over time from uncoated palbociclib, aluminum oxide-coated palbociclib, or titanium oxide-coated palbociclib as analyzed by UV spectroscopy. [Figure 15] Graph showing the crystallinity of compositions containing uncoated indomethacin, aluminum oxide coated indomethacin, or titanium oxide coated indomethacin with and without exposure to 90% relative humidity. [Figure 16] Representative images obtained by transmission electron microscopy of acetaminophen coated with metal oxide materials. [Figure 17] Graph showing the intensity versus binding energy profile for uncoated acetaminophen or acetaminophen compositions coated with metal oxide materials, as determined by XPS analysis; inset is a table showing the percentages of C1s, O1s, and N1s quantified from the graph. [Figure 18]Graph showing extracted ion chromatograms of intact mass of Avastin® from compositions of uncoated Avastin® or titanium oxide coated Avastin®. [Figure 19] Graph showing deconvoluted masses of predicted glycoforms and major heterogeneities detected in compositions of uncoated Avastin® or titanium oxide coated Avastin®. [Figure 20] Table showing the main heterogeneities detected by LC-MS of compositions of uncoated Avastin® or titanium oxide coated Avastin®. [Figure 21] Graph showing extracted ion chromatograms of intact mass of Herceptin® from compositions of uncoated Herceptin® or aluminum oxide coated Herceptin®. [Figure 22] Graph showing deconvoluted masses of predicted glycoforms and major heterogeneities detected in compositions of uncoated Herceptin® or aluminum oxide coated Herceptin®. [Figure 23] Table showing the main heterogeneities detected by LC-MS of compositions of uncoated Herceptin® or aluminum oxide coated Herceptin®. [Figure 24] 1 is a table showing the percentage of sequence coverage of dual digestion compositions of uncoated Avastin® or titanium oxide coated Avastin® compared to in-silico digested Avastin® sequences. [Figure 25] Plot showing all compounds identified in compositions of uncoated Avastin® or titanium oxide coated Avastin®. [Figure 26]Table showing the percentage of sequence coverage of dual digest compositions of uncoated Herceptin® or aluminum oxide coated Herceptin® compared to in-silico digested Herceptin® sequences. [Figure 27] Plot showing all compounds identified in compositions of uncoated Herceptin® or aluminum oxide coated Herceptin®. [Figure 28] Graph showing the results of FTIR analysis of compositions of uncoated Avastin® or titanium oxide coated Avastin®. [Figure 29] Graph showing the results of FTIR analysis of compositions of uncoated Avastin® or titanium oxide coated Avastin®. [Figure 30] Table showing the percentage of alpha helix, beta sheet, random coil, and beta turn of Avastin® from compositions of uncoated Avastin® or titanium oxide coated Avastin®. [Figure 31] Graph showing the results of far-UV CD analysis of compositions of uncoated Avastin® or titanium oxide coated Avastin®. [Figure 32] Graph showing the results of intrinsic and extrinsic fluorescence analysis of compositions of uncoated Avastin® or titanium oxide coated Avastin®. [Figure 33] Table showing λmax for compositions of uncoated Avastin® or titanium oxide coated Avastin® [Figure 34] Graph showing the results of FTIR analysis of compositions of uncoated Herceptin® or aluminum oxide coated Herceptin®. [Figure 35]Graph showing the results of FTIR analysis of compositions of uncoated Herceptin® or aluminum oxide coated Herceptin®. [Figure 36] Table showing the percentage of alpha helix, beta sheet, random coil, and beta turn of Herceptin® from compositions of uncoated Herceptin® or aluminum oxide coated Herceptin®. [Figure 37] Graph showing the results of far-UV CD analysis of compositions of uncoated Herceptin® or aluminum oxide coated Herceptin®. [Figure 38] Graph showing the results of near-UV CD analysis of compositions of uncoated Herceptin® or aluminum oxide coated Herceptin®. [Figure 39] (Top): Graph showing the results of size exclusion chromatography analysis of compositions of uncoated Avastin® or titanium oxide coated Avastin®; (Bottom): Table showing the retention times of quantified monomers and aggregates. [Figure 40] Graph showing the results of ion exchange chromatography analysis of compositions of uncoated Avastin® or titanium oxide coated Avastin®. [Figure 41] (Top): Graph showing the results of size exclusion chromatography analysis of compositions of uncoated Herceptin® or aluminum oxide coated Herceptin®; (Bottom): Table showing the retention times of quantified monomers and aggregates. [Figure 42] Graph showing the results of ion exchange chromatography analysis of compositions of uncoated Herceptin® or aluminum oxide coated Herceptin®. [Figure 43]Graph showing the results of an SPR binding assay of Avastin® isolated from uncoated Avastin® or titanium oxide coated Avastin® compositions. [Figure 44] Table showing KD values ​​quantified from the results shown in Figure 43 [Figure 45] Graph showing the results of an SPR binding assay of Herceptin® isolated from compositions of uncoated Herceptin® or aluminum oxide coated Herceptin®. [Figure 46] Table showing KD values ​​quantified from the results shown in Figure 45 [Figure 47] Table showing the percentage of secondary structure of Avastin® over time as measured by FTIR from compositions of uncoated Avastin® or titanium oxide coated Avastin®. [Figure 48] Table showing the λmax of Avastin® over time as measured by FTIR from compositions of uncoated Avastin® or titanium oxide coated Avastin®. [Figure 49] Graph showing the results of Avastin® intrinsic and extrinsic fluorescence over time for compositions of uncoated Avastin® or titanium oxide coated Avastin®. [Figure 50] Graph showing percentage of Avastin® aggregates as measured by SEC over time for compositions of uncoated Avastin® or titanium oxide coated Avastin®. [Figure 51] Table showing percentage of aggregates quantified from the results presented in Figure 50 [Figure 52] Table showing the percentage of secondary structure of Herceptin® over time as measured by FTIR from compositions of uncoated Herceptin® or aluminum oxide coated Herceptin®. [Figure 53] Table showing λmax of Herceptin® over time as measured by FTIR from compositions of uncoated Herceptin® or aluminum oxide coated Herceptin® [Figure 54] Graph showing the results of Herceptin® intrinsic and extrinsic fluorescence over time for compositions of uncoated Herceptin® or aluminum oxide coated Herceptin®. [Figure 55] Graph showing the percentage of Herceptin® aggregates as measured by SEC over time for compositions of uncoated Herceptin® or aluminum oxide coated Herceptin®. [Figure 56] Table showing percentage of aggregates quantified from the results presented in Figure 55 DETAILED DESCRIPTION OF THE INVENTION

[0026] The present disclosure provides methods for preparing pharmaceutical compositions containing a drug encapsulated by one or more layers of metal oxide. Such pharmaceutical compositions have improved flowability, solubility, and stability over time, and contain a high fraction of the drug that is functional before or after administration of the pharmaceutical composition to a subject in need. Generally, the provided methods for preparing pharmaceutical compositions can safely, reliably, and predictably produce pharmaceutical compositions with the aforementioned properties. As a result, the provided pharmaceutical compositions and methods for preparing metal oxide-encapsulated drugs have increased therapeutic value, increased commercial value, and reduced manufacturing costs per therapeutic dose.

[0027] The production of advantageous pharmaceutical compositions has been made possible by the discovery that the entire process can be carried out at lower temperatures, for example, not exceeding 35°C, by sequentially applying a vapor or gaseous metal precursor and a vapor or gaseous oxidizing agent (and performing one or more pump-purge cycles using an inert gas after each application of the metal or oxidizing agent). Known processes for coating drugs with metal oxides using vapor or gaseous precursors, when carried out at temperatures below 50°C, do not produce pharmaceutical compositions with improved properties because the level of oxidizing agent (e.g., water) in the reactor increases when the temperature drops below 50°C. Elevated and sustained levels of oxidizing agent in the reactor can adversely affect the reaction (and adsorption) of the metal precursor and oxidizing agent with the particle surfaces and with each other. In addition, elevated oxidant levels in the reactor can hinder the ability to remove unreacted metal precursors, gaseous by-products resulting from the reaction of the metal precursor with exposed hydroxyl groups on the substrate or particle surface, and / or unreacted oxidant not incorporated into the metal oxide layer around the drug, which can lead to the formation of contaminating metal oxide particles and / or reduced predictability regarding the number and uniformity of the metal oxide layer formed around the drug. Without being bound by any particular theory, the pump-purge cycle step may mediate a kinetic effect that knocks off oxidant molecules on the particle surface and the inner surface of the reactor that are trapped there kinetically, rather than thermodynamically. As a result, the problematic water content in the reactor is reduced to below the amount expected based on thermodynamic principles well known in the art, which are determined by the pressure, temperature, and number of molecules in the reactor.

[0028] Provided herein are methods utilizing mechanical systems and chemical engineering processes. The disclosure also provides exemplary components and operating conditions for the systems and processes, as well as exemplary drug substrates, vapor and gaseous metal precursors, and vapor and gaseous oxidizers.

[0029] drugs The term "drug" in its broadest sense includes small molecules, virus particles, polypeptides, polynucleotides, compositions comprising polypeptides, polypeptides and lipids, and compositions comprising polynucleotides and lipids. Drugs include analgesics, anesthetics, anti-inflammatory agents, anthelmintics, antiarrhythmic agents, antiasthmatic agents, antibiotics, anticancer agents, anticoagulants, antidepressants, antidiabetic agents, antiepileptic agents, antihistamines, antitussives, antihypertensive agents, antimuscarinics, antimycobacterial agents, antineoplastic agents, antioxidants, antipyretics, immunosuppressants, immunostimulants, antithyroid agents, antivirals, anxiolytics and sedatives, hypnotics, neuroleptics, astringents, bacteriostatic agents, beta-adrenergic receptor blocking agents, blood products, blood substitutes, bronchodilators, buffering agents, cardiac inotropes, chemotherapeutic agents, contrast media, corticosteroids, and the like. The agent may be selected from the group consisting of: an antihistamine, a cough suppressant, an expectorant, a mucolytic, a diuretic, a dopamine agonist, an antiparkinsonian, a free radical scavenger, a growth factor, a hemostatic agent, an immunological agent, a lipid regulating agent, a muscle relaxant, a protein, a peptide, a polypeptide, a parasympathomimetic, a parathyroid calcitonin, a bisphosphonate, a prostaglandin, a radiopharmaceutical, a hormone, a sex hormone, an antiallergic agent, an appetite stimulant, an appetite suppressant, a steroid, a sympathomimetic, a thyroid agent, a vaccine, a vasodilator, and a xanthine.

[0030] Exemplary types of small molecule drugs include, but are not limited to, acetaminophen, clarithromycin, azithromycin, ibuprofen, fluticasone propionate, salmeterol, pazopanib HCl, palbociclib, and amoxicillin-clavulanate potassium. Exemplary types of polypeptide drugs include, but are not limited to, proteins (e.g., antibodies), peptide fragments (e.g., antibody fragments), alemtuzumab, bevacizumab, cetuximab, gemtuzumab ozogamicin, ipilimumab, ofatumumab, panitumumab, pembrolizumab, ranibizumab, rituximab, or trastuzumab. Exemplary types of polynucleotide drugs include, but are not limited to, one or more of DNA, RNA, including messenger mRNA (mRNA), hybrids thereof, RNAi inducers, RNAi agents, siRNA, shRNA, miRNA, antisense RNA, ribozymes, catalytic DNA, triple-helix-forming guide RNA, aptamers, and vectors. Exemplary types of lipids include, but are not limited to, fats, waxes, sterol-containing metabolites, vitamins, fatty acids, glycerolipids, glycerophospholipids, sphingolipids, glycolipids, and polyketides, and prenol lipids.

[0031] In the present disclosure, the drug loaded into the reactor can be in powder form. Exemplary methods for preparing drugs in powder form include, but are not limited to, processes utilizing lyophilization, freeze-drying, precipitation, and dry compression.

[0032] Metal Oxide Materials The term "metal oxide material" in its broadest sense includes all materials formed from the reaction of elements considered to be metals with oxygen-based oxidizing agents. Exemplary metal oxide materials include, but are not limited to, aluminum oxide, titanium oxide, iron oxide, gallium oxide, magnesium oxide, zinc oxide, niobium oxide, hafnium oxide, tantalum oxide, lanthanum oxide, and zirconium dioxide. Exemplary oxidizing agents include, but are not limited to, water, ozone, and inorganic peroxides.

[0033] Atomic Layer Deposition (ALD) Atomic layer deposition is a thin film deposition technique that allows the deposition of films with controlled thickness and uniformity down to the atomic or molecular monolayer level by sequentially adding self-limiting monolayers of elements or compounds. Self-limiting means that only a single atomic layer is formed at a time; subsequent process steps are required to regenerate the surface to allow further deposition.

[0034] Chemical Vapor Deposition (CVD) Chemical vapor deposition is a thin film deposition technique in which elements or compounds are deposited on a surface by chemical reaction in the gas phase or on the surface. It differs from atomic layer deposition in that the deposition is not self-limiting, i.e., the film continues to grow as long as chemicals are supplied. It differs from physical vapor deposition in that the chemical reaction results in a deposited film that is chemically distinct from the precursor species.

[0035] Reactor System The term "reactor system" in its broadest sense includes all systems that can be used to perform ALD or mixed ALD / CVD or CVD. An exemplary reactor system is shown in FIG. 1 and described further below.

[0036] FIG. 1 illustrates a reactor system 10 for performing coating of particles, such as heat-sensitive particles, with a thin film coating. The reactor system 10 can perform the coating using ALD and / or CVD coating conditions. The relative contributions of the ALD and CVD processes to the thin film coating can be controlled by appropriate selection of process conditions. In particular, the reactor system 10 allows for a primarily, e.g., almost entirely, ALD process to be performed at a low processing temperature, e.g., below 50°C, e.g., 35°C or below. For example, the reactor system 10 can form a thin film metal oxide on the particles primarily by ALD at temperatures between 22°C and 35°C, e.g., between 25°C and 35°C, between 25°C and 30°C, or between 30°C and 35°C. Generally, the particles can remain or be maintained at such temperatures. This can be achieved by maintaining or maintaining the reactant gases and / or the interior surfaces of the reactor chamber (e.g., chamber 20 and drum 40, discussed below) at such temperatures.

[0037] By performing the ALD reaction at low temperature conditions, a coating can be formed on the particles without degrading the biological component, e.g., a vaccine or biopharmaceutical component. For example, an amorphous form of the biological component can be coated without destroying the biological component or converting the biological component to a crystalline form.

[0038] Reactor system 10 includes a stationary vacuum chamber 20 coupled to a vacuum pump 24 by a vacuum tube 22. Vacuum pump 24 can be an industrial vacuum pump sufficient to establish a pressure of less than 1 Torr, e.g., 1 to 100 mTorr, e.g., 50 mTorr. Vacuum pump 24 allows chamber 20 to be maintained at a desired pressure and allows for the removal of reaction by-products and unreacted process gases.

[0039] During operation, reactor 10 performs an ALD thin film coating process by introducing gaseous precursors of the coating into chamber 20. The gaseous precursors are alternately spiked into the reactor. This allows the ALD process to be a solvent-free process. The half-reactions of the ALD process are self-limiting, providing angstrom-level control of deposition. Additionally, the ALD reaction can be performed at low temperature conditions, such as below 50°C, e.g., below 35°C.

[0040] Chamber 20 is also coupled to a chemical delivery system 30. Chemical delivery system 20 includes three or more gas sources 32a, 32b, and 32c coupled to vacuum chamber 20 by respective delivery conduits 34a, 34b, and 34c and controllable valves 36a, 36b, and 36c. Chemical delivery system 30 may include a combination of restrictors, gas flow controllers, pressure transducers, and ultrasonic flow meters to provide controllable flow rates of various gases into chamber 20. Chemical delivery system 30 may also include one or more temperature control components, such as heat exchangers, resistance heaters, or heat lamps, to heat or cool the various gases before they enter chamber 20. While FIG. 1 shows separate gas lines running parallel to the chamber for each gas source, two or more gas lines may be combined, for example, with one or more three-way valves, before the combined lines reach chamber 20. Additionally, although three gas sources are shown in FIG. 1, four gas sources may be used to enable the in situ formation of layered structures having alternating layers of two different metal oxides.

[0041] The two gas sources supply two chemically distinct gaseous reactants for the coating process to the chamber 20. Suitable reactants include any one or combination of the following: monomer vapors, metal organics, metal halides, oxidizers such as ozone or water vapor, and polymer or nanoparticle aerosols (dry or wet). For example, the first gas source 32a can supply gaseous trimethylaluminum (TMA) or titanium tetrachloride (TiCl4), while the second gas source 32b can supply water vapor.

[0042] One of the gas sources can provide a purge gas. In particular, the third gas source can provide a gas that is chemically inert to the reactants, coating, and particles being processed. For example, the purge gas can be N2 or a noble gas such as argon.

[0043] A rotatable coating drum 40 is held within chamber 20. Drum 40 may be connected to a motor 44 by a drive shaft 42 that extends through a sealed port in the sidewall of chamber 20. Motor 44 may rotate the drum at speeds between 1 and 100 rpm. Alternatively, the drum may be directly connected to a vacuum source via a rotary union.

[0044] The particles to be coated, shown as particle bed 50, are disposed within the interior volume 46 of drum 40. Drum 40 and chamber 20 may include sealable ports (not shown) that allow particles to be placed in and removed from drum 40.

[0045] The body of the drum 40 is provided by one or more of a porous material, a solid metal, and a perforated metal. The pores through the cylindrical side wall of the drum 40 may have dimensions of 10 μm.

[0046] During operation, as the drum 40 rotates, one of the gases flows from the chemical delivery system 30 into the chamber 20. The combination of fine pores (1-100 μm), holes (0.1-10 mm), or larger openings in the coating drum serve to confine particles within the coating drum while allowing for rapid delivery of precursor chemicals and pumping out by-products or unreacted species. The pores in the drum 40 allow gas to flow between the exterior of the drum 40, i.e., the reactor chamber 20, and the interior of the drum 40. In addition, the rotation of the drum 40 agitates the particles to keep them separated and ensures that a large surface area of ​​the particles remains exposed. This allows for rapid and uniform interaction of the particle surfaces with the process gas.

[0047] In some implementations, one or more temperature control components are incorporated into the drum 40 to allow for control of the temperature of the drum 40. For example, resistive heaters, thermoelectric coolers, or other components may be present in or on the sidewalls of the drum 40.

[0048] Reactor system 10 also includes a controller 60 coupled to various controllable components, such as vacuum pump 24, gas distribution system 30, motor 44, temperature control system, etc., to control the operation of reactor system 10. Controller 60 may also be coupled to various sensors, such as pressure sensors, flow meters, etc., to provide closed-loop control of the pressure of the gases within chamber 20.

[0049] Generally, the controller 60 can operate the reactor system 10 according to a "recipe," which specifies the operating values ​​of each controllable element as a function of time. For example, the recipe can specify the times for which the vacuum pump 24 operates, the times and flow rates of each gas source 32a, 32b, 32c, the rotational speed of the motor 44, etc. The controller 60 can receive the recipe as computer-readable data (e.g., stored on a non-transitory computer-readable medium).

[0050] The controller 60 and other computing devices that are part of the systems described herein can be implemented in digital electronic circuitry, or in computer software, firmware, or hardware. For example, the controller can include a processor that executes a computer program stored in a computer program product, such as a non-transitory machine-readable storage medium. Such computer programs (also known as programs, software, software applications, or code) can be written in any form of programming language, including compiled or interpreted languages, and can be deployed in any form, such as as a stand-alone program or as a module, component, subroutine, or other unit suitable for use in a computing environment. In some implementations, the controller 60 is a general-purpose programmable computer. In some implementations, the controller can be implemented using special-purpose logic circuitry, such as an FPGA (field-programmable gate array) or an ASIC (application-specific integrated circuit).

[0051] operation First, particles are loaded into drum 40 of reactor system 10. The particles may have a solid core containing a drug, such as one of the drugs described above. Once the access port is sealed, controller 60 operates reactor system 10 according to a recipe to form a thin film metal oxide layer on the particles.

[0052] In particular, two reactant gases are alternately supplied to the chamber 20, with each step of supplying a reactant gas being followed by a purge cycle in which an inert gas is supplied to the chamber 20 to purge the reactant gas and by-products used in the previous step. Additionally, one or more gases (e.g., reactant gas and / or inert gas) can be supplied in pulses, where the chamber 20 is filled with gas to a specified pressure, a delay time is allowed to elapse, and the chamber is evacuated by the vacuum pump 24 before the next pulse begins.

[0053] In particular, the controller 60 can operate the reactor system 10 as follows.

[0054] In the first reactant half-cycle, motor 44 rotates drum 40 to agitate particles 50 while i) The gas delivery system 30 is operated to flow a first reactant gas, e.g., TMA, from the gas source 32a into the chamber 20 until a first specified pressure is achieved. The specified pressure may be 0.1 Torr for half the saturation pressure of the reactant gas. ii) The flow of the first reactant is stopped and a specified delay time is allowed to pass, e.g., as measured by a timer in the controller, to allow the first reactant to flow through the particle bed in the drum 40 and react with the surfaces of the particles 50 in the drum 40. iii) The vacuum pump 50 evacuates the chamber 20, for example to a pressure below 1 Torr, for example 1-100 mTorr, for example 50 mTorr.

[0055] These steps (i) to (iii) can be repeated a number of times set by the recipe, for example, 2 to 10 times, for example, 6 times.

[0056] Next, in a first purge cycle, the motor 44 rotates the drum to agitate the particles 50 while: iv) The gas distribution system 30 is operated to flow an inert gas, such as N2, from the gas source 32c into the chamber 20 until a second specified pressure is achieved, which may be between 1 and 100 Torr. v) The flow of inert gas is stopped and a specified delay time is allowed to pass, for example, as measured by a timer in the controller, to allow the inert gas to flow through the pores in the drum 40 and diffuse through the particles 50, eliminating the reactant gases and any vapor by-products. vi) The vacuum pump 50 evacuates the chamber 20, for example to a pressure below 1 Torr, for example 1-500 mTorr, for example 50 mTorr.

[0057] These steps (iv) to (vi) can be repeated a number of times set by the recipe, for example 6 to 20 times, for example 16 times.

[0058] In the second reactant half-cycle, motor 44 rotates drum 40 to agitate particles 50 while vii) The gas delivery system 30 is operated to flow a second reactant gas, e.g., HO, from the gas source 32a into the chamber 20 until a third specified pressure is achieved, which may be 0.1 Torr for half the saturation pressure of the reactant gas. viii) The flow of the second reactant is stopped and a specified delay time is allowed to pass, e.g., as measured by a timer in the controller, to allow the second reactant to flow through the pores in the drum 40 and react with the surfaces of the particles 50 within the drum 40. ix) The vacuum pump 50 evacuates the chamber 20, for example to a pressure below 1 Torr, for example 1-500 mTorr, for example 50 mTorr.

[0059] These steps (vii) to (ix) can be repeated a number of times set by the recipe, for example, 2 to 10 times, for example 6 times.

[0060] A second purge cycle is then performed, which may be identical to the first purge cycle or may have a different number of repetitions of steps (iv)-(vi) and / or a different delay time and / or a different pressure.

[0061] The cycle of first reactant half cycle, first purge cycle, second reactant half cycle, and second purge cycle can be repeated a number of times set by the recipe, for example, 1 to 10 times.

[0062] As noted above, the coating process can be carried out at low processing temperatures, e.g., below 50°C, e.g., 35°C or below. In particular, the particles can remain or be maintained at such temperatures during all of steps (i)-(ix) above. Generally, the temperature inside the reactor chamber does not exceed 35°C during steps (i)-(ix). This can be achieved by injecting the first reactant gas, the second reactant gas, and the inert gas into the chamber at such temperatures during each cycle. Additionally, the physical components of the chamber can be remained or maintained at such temperatures, as needed, for example, using a cooling system, e.g., a thermoelectric cooler.

[0063] Process for preparing a pharmaceutical composition comprising a drug encapsulated by one or more layers of a metal oxide Two exemplary methods are provided for pharmaceutical compositions comprising a drug-containing core surrounded by one or more metal oxide materials. The first exemplary method includes the following series of steps: (a) loading drug-containing particles into a reactor, (b) applying a vapor or gaseous metal precursor to the substrate in the reactor, (c) performing one or more pump-purge cycles of the reactor using an inert gas, (d) applying a vapor or gaseous oxidant to the substrate in the reactor, and (e) performing one or more pump-purge cycles of the reactor using an inert gas. During the method, the temperature of the particles does not exceed 35°C.

[0064] In some embodiments of the first exemplary method, the sequence of steps (b)-(e) is optionally repeated one or more times to increase the overall thickness of the one or more metal oxide materials surrounding the solid core of the coated particle. In some embodiments, the reactor pressure is allowed to stabilize during subsequent steps (a), (b), and / or (d). In some embodiments, the reactor contents are agitated before and / or during steps (b), (c), and / or (e). In some embodiments, a subset of the vapor or gaseous contents is pumped out before steps (c) and / or (e).

[0065] A second exemplary method includes: (a) loading drug-containing particles into a reactor; (b) reducing the reactor pressure to less than 1 Torr; (c) stirring the reactor contents until the reactor contents have a desired water content; (d) pressurizing the reactor to at least 10 Torr by adding a vapor or gaseous metal precursor; (e) stabilizing the reactor pressure; (f) stirring the reactor contents; (g) pumping out a subset of the vapor or gaseous contents and determining when to stop pumping based on an analysis of the reactor contents, including the metal precursor and by-products of the metal precursor that react with exposed hydroxyl residues on the substrate or particle surface; and (h) inertizing the reactor contents. The method includes (e.g., consists of) the following steps: (i) pressurizing the reactor to at least 10 Torr by adding a vapor or gaseous oxidant; (j) stabilizing the reactor pressure; (k) stirring the reactor contents; (l) pumping out a subset of the vapor or gaseous contents and determining when to stop pumping based on an analysis of the reactor contents, including the metal precursor reacting with exposed hydroxyl residues on the substrate or particle surface, by-products of the metal precursor, and unreacted oxidant; and (m) pumping out a series of pump-purge cycles of the reactor using an inert gas. During the method, the temperature of the particles does not exceed 35°C.

[0066] In some embodiments of the second exemplary method, the sequence of steps (b) through (m) is optionally repeated one or more times to increase the overall thickness of the one or more metal oxide materials surrounding the solid core of the coated particle.

[0067] Pharmaceutically acceptable excipients, diluents, and carriers Pharmaceutically acceptable excipients include, but are not limited to: (1) Surfactants and polymers, including: polyethylene glycol (PEG), polyvinylpyrrolidone (PVP), sodium lauryl sulfate, polyvinyl alcohol, crospovidone, polyvinylpyrrolidone-polyvinyl acrylate copolymers, cellulose derivatives, hydroxypropyl methylcellulose, hydroxypropyl cellulose, carboxymethylethyl cellulose, hydroxypropyl methylcellulose phthalate, polyacrylates and polymethacrylates, urea, sugars, polyols, carbomers and their polymers, emulsifiers, sugar gums, starches, organic acids and their salts, vinylpyrrolidone, and vinyl acetate; (2) Binders, such as cellulose, cross-linked polyvinylpyrrolidone, microcrystalline cellulose, etc.; (3) fillers, such as lactose monohydrate, anhydrous lactose, microcrystalline cellulose, and various starches; (4) lubricants, such as agents that affect the flowability of the powder being compressed, including colloidal silicon dioxide, talc, stearic acid, magnesium stearate, calcium stearate, silica gel, etc.; (5) Sweeteners, e.g., any natural or artificial sweetener, such as sucrose, xylitol, sodium saccharin, cyclamate, aspartame, and acesulfame K; (6) flavoring agents; (7) Preservatives, such as potassium sorbate, methylparaben, propylparaben, benzoic acid and its salts, other esters of parahydroxybenzoic acid such as butylparaben, alcohols such as ethyl or benzyl alcohol, phenolic compounds such as phenol, or quaternary compounds such as benzalkonium chloride; (8) Buffer; (9) Diluents, such as pharmaceutically acceptable inert fillers, such as microcrystalline cellulose, lactose, dibasic calcium phosphate, sugars, and / or mixtures of any of the foregoing; (10) Wetting agents, such as corn starch, potato starch, maize starch, modified starch, and mixtures thereof; (11) Disintegrants; for example, croscarmellose sodium, crospovidone, sodium starch glycolate, etc.; and (12) Effervescent agents, for example, effervescent couples such as organic acids (e.g., citric acid, tartaric acid, malic acid, fumaric acid, adipic acid, succinic acid, and alginic acid and anhydrides and acid salts), or carbonates (e.g., sodium carbonate, potassium carbonate, magnesium carbonate, sodium glycine carbonate, L-lysine carbonate, and arginine carbonate), or bicarbonates (e.g., sodium bicarbonate or potassium bicarbonate). [Example]

[0068] The following materials and methods were used in the examples described herein.

[0069] Example 1: Preparation of drug-containing particles encapsulated with a uniform and thin aluminum oxide coating layer with nanometer-level precision at a process temperature of 35°C or less In this example, one of the disclosed methods for preparing a drug encapsulated in a metal oxide is carried out and data is presented. In this example, the vapor or gaseous metal precursor is trimethylaluminum (TMA), the by-product gaseous methane is formed after TMA reacts with exposed hydroxyl groups on the particle or coated particle surface, and the oxidant is water vapor.

[0070] method Briefly, the method consists of the following series of steps: (a) loading drug-containing particles into a reactor; (b) reducing the reactor pressure to less than 1 Torr; (c) stirring the reactor contents until the reactor contents reach the desired water content by performing residual gas analysis (RGA) to monitor the level of water vapor in the reactor; (d) pressurizing the reactor to at least 1 Torr by adding vapor or gaseous TMA; (e) stabilizing reactor pressure; (f) stirring the contents of the reactor; (g) pumping out a subset of the vapor or gaseous contents, including gaseous methane and unreacted TMA, and determining when to stop pumping by performing an RGA to monitor the levels of gaseous methane and unreacted TMA in the reactor; (h) performing a series of pump-purge cycles on the reactor using nitrogen gas; (i) pressurizing the reactor to at least 1 Torr by adding water vapor; (j) stabilizing reactor pressure; (k) stirring the contents of the reactor; (l) pumping out a subset of the vapor or gaseous contents, including water vapor, and determining when to stop pumping by running an RGA to monitor the level of water vapor in the reactor; (m) performing a series of pump-purge cycles on the reactor using nitrogen gas;

[0071] During this process, the internal temperature of the reactor did not exceed 35°C. Additionally, steps (b) through (m) were repeated one more time to increase the overall thickness of the aluminum oxide surrounding the solid core. Figure 2 includes representative process conditions for carrying out this process.

[0072] result Figure 3 shows representative residual gas analysis traces taken during steps (d), (h), (i), and (m) for one cycle of this method. This method reproducibly demonstrates growth rates of metal oxide coatings of 2 to 4 angstroms per cycle. In contrast, alternative methods that limit growth to ALD demonstrated average growth of only 1 angstrom per cycle. Without being bound by theory, given the growth rates observed with this method, growth may be mediated by a combination of ALD and CVD.

[0073] Example 2: Determining whether encapsulation of small molecules with metal oxide coatings alters their structure or dissolution profile To assess whether encapsulation of small molecules with metal oxide coatings altered their structure or dissolution profile, the small molecules clarithromycin, clarithromycin-carbomer complex, pazopanib HCl, palbociclib, and amoxicillin-clavulanate potassium were encapsulated with metal oxide coatings, and the resulting particles were subjected to chemical analysis to determine whether the metal oxide coating altered their structure or dissolution profile. Small molecules in powder form were encapsulated by the method provided in this disclosure with the following modifications, as shown in the table below. TIFF2025170276000002.tif80170

[0074] method High-performance liquid chromatography Samples at a concentration of 1 mg / mL were prepared by dissolving the analyte in a 50:50 volume:volume mixture of acetonitrile and water and filtered through a 0.45 μm filter. The exact conditions of the analysis, including the mobile phase, column, and oven temperature, will vary depending on the analyte being studied. A typical example of the analysis uses a mobile phase consisting of 0.05 M pH 4 phosphate buffer mixed with acetonitrile (90:10 v / v), an Agilent Pursuit XRs 3C-18 3 μm column, an oven temperature of 37 °C, a flow rate of 0.9 mL / min, an injection volume of 35 μL, a run time of 5 minutes, and a UV detector at 214 nm.

[0075] Matrix-assisted laser desorption / ionization coupled to mass spectrometry (MALDI-MS) Samples were prepared by dissolving them in a water-acetonitrile mixture at a ratio of 18:82 v / v. The samples were then mixed with cyano-4-hydroxycinnamic acid matrix and loaded onto a MALDI chip. MS data acquisition was performed in reflectron positive mode.

[0076] result The results are shown in Figures 4-14. Compared to the uncoated control, the small molecule clarithromycin and clarithromycin-carbomer complex coated with either titanium oxide or aluminum oxide showed little or no change in structure, as detected by HPLC analysis. Compared to the uncoated control, the small molecule pazopanib HCl and palbociclib coated with either titanium oxide or aluminum oxide showed little or no change in structure, as detected by MALDI-MS analysis. Compared to the uncoated control, the small molecule clarithromycin, clarithromycin-carbomer complex, and palbociclib coated with either titanium oxide or aluminum oxide, and the aluminum oxide-coated pazopanib HCl showed little or no change in dissolution profile. In contrast, the small molecule pazopanib HCl coated with titanium oxide and the amoxicillin-clavulanate potassium coated with either titanium oxide or aluminum oxide showed altered dissolution profiles compared to the uncoated control. Titanium oxide coated pazopanib HCl exhibits an altered dissolution profile (similar initial release followed by delayed release) compared to the uncoated control. Titanium oxide coated amoxicillin clavulanate potassium exhibits an altered dissolution profile (slow initial release followed by rapid release without saturation at 30 minutes) compared to the uncoated control. Finally, aluminum oxide coated amoxicillin clavulanate potassium exhibits an altered dissolution profile (slow initial release followed by rapid release) compared to the uncoated control.

[0077] Conclusion: This example demonstrates that encapsulation of five small molecules with either titanium oxide or aluminum oxide does not result in a significant reduction in small molecule structure, but results in little to no change in dissolution profile, or a significant change, depending on the small molecule and / or metal oxide coating. While not wishing to be bound by any particular theory, Applicant notes that it is surprising that 1) the impact on dissolution profile can vary widely for the same coating material (based on process conditions, API, and dissolution conditions), and 2) coatings made with the same base material can have essentially no effect on the dissolution profile. This represents a versatile process that can generate dissolution profiles tailored to specific applications using the same base material. Applicant concludes that, as described herein, a skilled artisan can test various methods or parameters to generate small molecules coated with a selected metal coating that do not result in a significant reduction in structure and that may or may not exhibit a change in dissolution profile compared to the uncoated small molecule.

[0078] Example 3: Determining whether encapsulation of small molecules with metal oxide coatings retards crystallization of amorphous indomethacin exposed to moisture To assess whether encapsulation of small molecules with metal oxide coatings altered the structure or dissolution profile, the small molecule diclofenac was encapsulated with a metal oxide coating and the resulting particles were subjected to chemical analysis to determine whether the metal oxide coating altered the crystallinity of the amorphous diclofenac. Small molecules in powder form were encapsulated by the method provided in this disclosure with the following modifications as shown in the table below. TIFF2025170276000003.tif25170

[0079] method Evaluation of the crystallinity of amorphous indomethacin Amorphous indomethacin was prepared by lyophilization of a standard indomethacin sample, and the crystalline content was measured by differential scanning calorimetry (DSC) before and after exposure to moisture. The area under the crystallization peak was used to determine the specific heat of crystallization of the amorphous material. The percent crystallinity of the partially crystalline material was determined by dividing the heat of crystallization by the heat of crystallization of the completely amorphous material, subtracting that value from 1, and multiplying by 100.

[0080] result Compared to uncoated controls, small molecule indomethacin coated with either titanium oxide or aluminum oxide showed reduced conversion from the amorphous to the crystalline state in the as-treated state and after exposure to 90% relative humidity (RH) (Figure 15).

[0081] Conclusion: This example provides guidance that the provided methods can produce small molecules coated with more stable metal oxide materials, specifically such that the drug in the coated particles exhibits reduced conversion from the amorphous state to the crystalline state both as-processed and after exposure to stress, such as 90% RH.

[0082] Example 4: Determining whether the provided method allows for uniform and conformal thin metal oxide coatings on small molecules To assess whether the provided methods allow for uniform, conformal thin metal oxide coatings on small molecules, acetaminophen was coated with metal oxide materials by the methods of the present disclosure and analyzed by atomic layer microscopy and XPS analysis. Small molecules in powder form were encapsulated by the methods provided in the present disclosure.

[0083] method Transmission electron microscopy Samples for TEM were prepared using the in situ FIB lift-out technique on an FEI Strata 400 Dual Beam FIB / SEM. Prior to milling, samples were capped with protective carbon and e-Pt / I-Pt. The thickness of the TEM lamella was approximately 100 nm. Samples were imaged on an FEI Tecnai TF-20 FEG / TEM operating at 200 kV in bright-field (BF) TEM mode and high-resolution (HR) TEM mode. Qualitative elemental maps of the images were obtained using energy dispersive spectroscopy (EDS).

[0084] XPS analysis X-ray photoelectron spectroscopy (XPS) was performed on the samples to obtain details of the surface chemistry before and after coating. Powder samples were mounted on adhesive substrates and loaded into the instrument. Soft X-rays (1486 eV) were used to excite the samples, with an X-ray penetration depth of 5 nm and a spot size of 200 μm.

[0085] result Direct TEM imaging of cross sections prepared by focused ion beam (FIB) milling of coated acetaminophen particles shows uniform and conformal coating of the drug particles with aluminum oxide at the nanometer scale, regardless of location on the particle (Figure 16). Energy dispersive spectroscopy (EDS) qualitatively demonstrated that the coating consisted essentially of aluminum and oxygen (Figure 17).

[0086] Conclusion: This example provides guidance that the presented method enables uniform and conformal thin metal oxide coatings on small molecules with nanometer-level precision.

[0087] Example 5. Determining whether encapsulation of lyophilized monoclonal antibodies (mAbs) with metal oxide coatings alters the structure, stability, or ability of the mAbs to bind to target polypeptides To assess whether encapsulation of lyophilized mAbs with metal oxide coatings alters the structure or stability of the mAbs, the mAbs trastuzumab (Herceptin®) and bevacizumab (Avastin®) were encapsulated with metal oxide coatings, and the resulting particles were subjected to biochemical and chemical analyses to determine whether the metal oxide coating altered the mAb's structure, stability, or ability to bind to a target polypeptide. The two mAbs were encapsulated by the methods provided in this disclosure with the following modifications: (1) for Herceptin®, 99 consecutive cycles were performed before the coated particles were mixed with a pharmaceutically acceptable diluent or carrier, and the vapor or gaseous metal precursor was aluminum oxide (Al2O3); (2) for Avastin®, 49 consecutive cycles were performed before the coated particles were mixed with a pharmaceutically acceptable diluent or carrier, and the vapor or gaseous metal precursor was titanium oxide (TiO2).

[0088] method Liquid chromatography coupled with mass spectrometry Reversed-phase chromatography (RPC) was performed on an AdvanceBio RP mab C4 (Agilent Technologies) column using an Agilent 1260 Infinity Bio-inert Quaternary LC system connected to an Agilent 6230 electrospray ionization time-of-flight mass spectrometer (ESITOF-MS) instrument, with mobile phase A (0.1% (v / v) FA) and 10% mobile phase B (0.1% (v / v) FA in acetonitrile). Samples were buffer-exchanged through a 10 kDa MWCO Centricon (Pall Corporation) column, loaded onto the column, and separated using a linear gradient of 10%–65% B at a flow rate of 0.5 ml / min. MS spectra were calibrated in positive ion mode, and TICs were recorded from 1,000 to 7,000 m / z. The capillary gas temperature / voltage (Vcap) was set at 350 °C / 5,500 V, respectively, and the fragmentor voltage (Vfrag) was 400 V. MS spectra were deconvoluted using the maximum entropy (MaxEnt) algorithm as part of Agilent MassHunter Qualitative Analysis and BioConfirm software.

[0089] Peptide mapping Reversed-phase chromatography (RPC) was performed on an AdvanceBio Peptide Mapping C18 (Agilent Technologies) column operated at 55 °C using an Agilent 1260 Infinity Bio-inert Quaternary LC system connected to an Agilent 6230 ESI-TOF-MS instrument, with mobile phase A (0.1% (v / v) TFA) and mobile phase B (0.1% (v / v) TFA in acetonitrile). The digested sample was injected onto the column and separated using a linear gradient from 5% to 65% B at a flow rate of 0.3 ml / min. MS spectra were calibrated in positive ion mode, and TICs were recorded from 100 to 3200 m / z. The capillary gas temperature and Vcap were set to 300 °C and 4500 V, respectively, and Vfrag was 300 V. The MS spectra were analyzed using the protein molecular feature extraction (MFE) algorithm in Agilent MassHunter Qualitative Analysis and BioConfirm software to obtain a list of potential peptides, which were matched with the in-silico digested mAb peptides to obtain sequence coverage.

[0090] Fourier transform infrared spectroscopy (FTIR) FTIR spectra were recorded at room temperature using attenuated total reflectance (ATR). The FTIR absorbance spectrum of 0.5 mg / ml mAb was recorded between 500 and 4000 cm. -1 The second derivative spectrum was obtained by applying 11-point Savitzky-Golay smoothing to the original spectrum. The Savitzky-Golay smoothing was performed at 700 cm. -1 The second derivative spectra in the range of 1660–1654 cm were deconvoluted by curve fitting using the Levenberg–Marquardt algorithm to identify the α-helix (1660–1654 cm). -1 ), β-sheet (1637~1614cm -1 ), Turn (1678~1670cm -1 ), random coil (1648~1638cm -1 ) and β-antiparallel (1691~1680cm -1The peaks corresponding to the conformational regions were adjusted and the area was measured using a Gaussian function. The areas of all component bands assigned to a given conformation were then summed and divided by the total area.

[0091] Circular dichroism (CD) Far-UV CD spectra were recorded in the range of 200–250 nm at 25°C using a 0.1 cm pathlength quartz cell at a scan rate of 50 nm / min with a spectral bandwidth of 5 nm. The sample concentration was maintained at 0.2 mg / ml, and three spectra were scanned, averaged, and finally plotted after subtracting the buffer baseline. The mean residue ellipticity (MRE, deg cm / dmole) was calculated.

[0092] Fluorescence spectroscopy Intrinsic fluorescence was measured by exciting a protein solution (0.5 mg / ml) at 295 nm (tryptophan excitation only). Emission spectra were recorded in the range of 300–450 nm. The external fluorescence intensity of the sample (0.5 mg / ml) was recorded in a fluorescence spectrophotometer using ANS (8-anilinonaphthalene-1-sulfonic acid) dye with an excitation of 380 nm and an emission of 400–600 nm. All measurements were performed in triplicate. Each spectrum represents the average of three scans.

[0093] Size Exclusion Chromatography (SEC-HPLC) Size exclusion chromatography was performed on a Superdex 200 column using a Dionex Ultimate 3000 UHPLC system (Thermo Scientific) with a buffer of 300 mM NaCl and 0.05% NaN at pH 6.8. Detection was by monitoring UV absorbance at 280 nm. Peak integration and peak area were determined using Chromeleon software.

[0094] Cation Exchange Chromatography (CEX) Ion-exchange chromatography was performed using a Dionex Ultimate 3000 RSLC system (Thermo Scientific) with an Agilent Bio MAb NP5 column and a buffer of 300 mM NaCl and 0.05% NaN at pH 6.8. Detection was by monitoring UV absorbance at 280 nm.

[0095] Surface plasmon resonance (SPR) FcRn binding kinetics assay The binding kinetics of various mAb samples to the human FcRn receptor were measured using surface plasmon resonance (SPMR) on a Biacore X100™ (GE Healthcare) in HBS-EP buffer (GE Healthcare Life Sciences). Recombinant human FcRn antibodies were immobilized, and samples were injected at a range of concentrations. Rate constants were calculated from the sensorgrams using a 1:1 fit model with BIA Evaluation 2.0.1 software.

[0096] Stability analysis To determine the structural integrity and aggregation of metal oxide-coated mAbs over 10 days at 80 °C, the higher-order structure of the mAb was measured by Fourier transform infrared spectroscopy (FTIR), the tertiary structure of the mAb was measured by intrinsic and extrinsic fluorescence analysis, and the size variant profile was measured by size exclusion chromatography (SEC). Samples were stored in a dry bath at 80 °C and sampled at designated times for testing. FTIR spectra were recorded at room temperature using attenuated total reflectance (ATR). FTIR absorbance spectra of 0.5 mg / ml mAb were recorded from 500 to 4000 cm. -1 The second derivative spectrum was obtained by applying 11-point Savitzky-Golay smoothing to the original spectrum. -1 The second derivative spectra in the range of 1660–1654 cm were deconvoluted by curve fitting using the Levenberg–Marquardt algorithm to identify the α-helix (1660–1654 cm). -1), β-sheet (1637~1614cm -1 ), Turn (1678~1670cm -1 ), random coil (1648~1638cm -1 ) and β-antiparallel (1691~1680cm -1 The peaks corresponding to the corresponding conformations were adjusted and their areas were measured using a Gaussian function. The areas of all component bands assigned to a given conformation were then summed and divided by the total area. Intrinsic fluorescence was measured by exciting the protein solution (0.5 mg / ml) at 295 nm (tryptophan excitation only). Emission spectra were recorded in the range of 300–450 nm. The external fluorescence intensity of the sample (0.5 mg / ml) was recorded using a fluorescence spectrophotometer with ANS (8-anilinonaphthalene-1-sulfonic acid) dye at 380 nm excitation and 400–600 nm emission. All measurements were performed in triplicate. Each spectrum represents the average of three scans. Size-exclusion chromatography was performed as described above.

[0097] result Liquid chromatography coupled with mass spectrometry was performed to confirm the mass and sequence identity of the mAb encapsulated in the metal coating. Results for Avastin® are shown in Figures 18-20. The data suggest that the titanium oxide coating has little or no effect on the intact protein mass of Avastin®. With one exception, the predicted changes in coated Avastin® were consistent with those of uncoated Avastin®. Results for Herceptin® are shown in Figures 21-23. The data suggest that the aluminum oxide coating has little or no effect on the intact protein mass of Herceptin® compared to uncoated Avastin®.

[0098] Peptide mapping was performed to confirm the sequence identity and post-translational modifications of the mAb encapsulated in the metal coating. Results for Avastin® are shown in Figures 24-25. The data suggest that the titanium oxide coating has little or no effect on the sequence identity of Avastin® when compared to in-silico digested Avastin®.

[0099] The results for Herceptin® are shown in Figures 26-27. The data suggest that the aluminum oxide coating has little or no effect on the sequence identity of Herceptin® when compared to in-silico digested Herceptin®.

[0100] Fourier transform infrared (FTIR) spectroscopy and circular dichroism (CD) analysis were performed to determine whether there were any changes in the secondary structure of the mAb. Fluorescence spectroscopy was performed to determine whether there were any changes in the tertiary structure of the mAb. Results for Avastin® are shown in Figures 28-33. The data suggest that the titanium oxide coating has little or no effect on the secondary structure of Avastin® when compared to uncoated Avastin®. Results for Herceptin® are shown in Figures 34-38. The data suggest that the aluminum oxide coating has little or no effect on the secondary structure of Herceptin® when compared to uncoated Herceptin®, as determined by FTIR. The data suggest that the aluminum oxide coating has little or no effect on the tertiary structure of Herceptin® when compared to uncoated Herceptin®, as detected by far-UV and near-UV circular dichroism analysis.

[0101] Size exclusion chromatography (SEC) was performed to determine whether there were any changes in the size variants of the mAb samples. Cation exchange chromatography (CEX) was performed to determine whether there were any changes in the charge variant profile of the mAb samples. The results for Avastin® are shown in Figures 39-40. The data suggest that titanium oxide coating has little or no effect on the percentage of monomers and aggregates or the percentage of charge variants of Avastin® compared to uncoated Avastin®. The results for Herceptin® are shown in Figures 40-41. The data suggest that aluminum oxide coating has little or no effect on the percentage of monomers and aggregates or the percentage of charge variants of Herceptin® compared to uncoated Herceptin®.

[0102] To determine the functionality of the mAbs, binding kinetics were determined by surface plasmon resonance (SPR). Results for Avastin® are shown in Figures 43-44. The data suggest that titanium oxide-coated Avastin® exhibited four-fold stronger binding (reflected by a reduced KD) to the target human FcRn receptor compared to uncoated Avastin®. Results for Herceptin® are shown in Figures 45-46. The data suggest that aluminum oxide-coated Herceptin® exhibited similar binding (reflected by a similar KD value) to the target human FcRn receptor compared to uncoated Herceptin®.

[0103] To determine the structural integrity and aggregation of metal oxide-coated mAbs over 10 days at 80°C, the secondary structure of the mAb was measured by Fourier transform infrared spectroscopy (FTIR), the tertiary structure of the mAb was measured by intrinsic and extrinsic fluorescence analysis, and the size variant profile was measured by size exclusion chromatography (SEC). Results for Avastin® are shown in Figures 47-51. The data suggest that titanium oxide-coated Avastin® exhibits little or no change in the level of mAb secondary or tertiary structure as detected by FTIR and fluorescence analysis, respectively, compared to uncoated Avastin®. The data also suggest that titanium oxide-coated Avastin® exhibits a reduced rate of aggregate accumulation, as determined by SEC, compared to uncoated Avastin®. Results for Herceptin® are shown in Figures 52-56. The data suggest that titanium oxide coated Herceptin® shows little or no change at the level of mAb secondary or tertiary structure compared to uncoated Herceptin® as detected by FTIR and fluorescence analysis, respectively. The data also suggest that titanium oxide coated Herceptin® shows similar aggregate accumulation rates as determined by SEC compared to uncoated Herceptin®.

[0104] Conclusion: This example demonstrates that encapsulation of two different lyophilized mAbs with a metal coating does not result in significant degradation of the mAb's structure, stability, or ability to bind to a target polypeptide (e.g., human FcRn). Notably, titanium oxide-coated Herceptin® exhibited four-fold stronger binding (reflected by a reduced KD) to the target human FcRn receptor compared to uncoated Avastin®. Also noteworthy is that titanium oxide-coated Avastin® exhibited a reduced rate of aggregate accumulation at 80°C for 10 days compared to uncoated Avastin®, as determined by SEC. Applicants conclude that one skilled in the art can test various methods or parameters described herein to produce lyophilized mAbs coated with a metal coating of their choice that do not significantly degrade mAb structure, stability, or ability to bind to a target polypeptide.

Claims

1. 1. A method for preparing a pharmaceutical composition comprising a drug-containing core surrounded by one or more metal oxide materials, comprising: (a) loading drug-containing particles into a reactor; (b) applying a vapor or gaseous metal precursor to the particles in the reactor; (c) performing one or more pump-purge cycles of the reactor using an inert gas; (d) applying a vapor or gaseous oxidant to the particles in the reactor; and (e) performing one or more pump-purge cycles of the reactor using an inert gas; It includes a series of steps: the temperature of the particles does not exceed 35°C, thereby producing a pharmaceutical composition comprising a drug-containing core surrounded by one or more metal oxide materials; method.

2. 10. The method of claim 1, wherein the sequence of steps (b) through (e) is repeated one or more times to increase the overall thickness of the one or more metal oxide materials surrounding the core.

3. 10. The method of claim 1, wherein the reactor pressure is stabilized during the following steps (a), (b), and / or (d).

4. 10. The method of claim 1, wherein the contents of the reactor are agitated before and / or during step (b), step (c), and / or step (e).

5. 10. The method of claim 1, wherein a subset of the vapor or gaseous contents is pumped out prior to step (c) and / or step (e).

6. The method of claim 1 , wherein the metal oxide layer has a thickness in the range of 0.1 nm to 100 nm.

7. The method of claim 1 , wherein the particles comprise a drug and one or more pharmaceutically acceptable excipients.

8. 10. The method of claim 1, wherein the particles have a median particle size, on a volume average basis, between 0.1 μm and 1000 μm.

9. 10. The method of claim 1, wherein the pharmaceutical composition is removed from the reactor and mixed with a pharmaceutically acceptable diluent or carrier.

10. The method of claim 1 , wherein the particles consist essentially of the drug.

11. The method of claim 1 , wherein the drug is a small molecule, a viral particle, a polypeptide, a polynucleotide, a composition comprising a polypeptide and a lipid, or a composition comprising a polynucleotide and a lipid.

12. 1. A pharmaceutical composition comprising a drug-containing core surrounded by one or more metal oxide materials, the method comprising: (a) loading drug-containing particles into a reactor; (b) applying a vapor or gaseous metal precursor to the particles in the reactor; (c) performing one or more pump-purge cycles of the reactor using an inert gas; (d) applying a vapor or gaseous oxidant to the particles in the reactor; and (e) performing one or more pump-purge cycles of the reactor using an inert gas; It includes a series of steps: the temperature of the particles does not exceed 35°C, thereby producing a pharmaceutical composition comprising a drug-containing core surrounded by one or more metal oxide materials; Pharmaceutical compositions.

13. 13. The composition of claim 12, wherein the sequence of steps (b) through (e) is repeated one or more times to increase the overall thickness of the one or more metal oxide materials surrounding the core.

14. 13. The composition of claim 12, wherein the reactor pressure stabilizes the following steps (a), (b), and / or (d).

15. 13. The composition of claim 12, wherein the contents of the reactor are agitated before and / or during step (b), step (c), and / or step (e).

16. 13. The composition of claim 12, wherein a subset of the vapor or gaseous contents is pumped out prior to step (c) and / or step (e).

17. 13. The composition of claim 12, wherein the metal oxide layer has a thickness in the range of 0.1 nm to 100 nm.

18. The composition of claim 12 , wherein the particles comprise a drug and one or more pharmaceutically acceptable excipients.

19. 13. The composition of claim 12, wherein the particles have a median particle size, on a volume average basis, between 0.1 μm and 1000 μm.

20. 13. The composition of claim 12, wherein the pharmaceutical composition is removed from the reactor and mixed with a pharmaceutically acceptable diluent or carrier.

21. The composition of claim 12 , wherein the core consists essentially of the drug.

22. The composition of claim 12 , wherein the drug is a small molecule, a viral particle, a polypeptide, a polynucleotide, a composition comprising a polypeptide and a lipid, or a composition comprising a polynucleotide and a lipid.

Images